Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Introduction
Parkinson's disease (PD) is a widespread neurodegenerative disorder. Even though the neurochemical defects and the neuropathological characteristics of this disease are well defined, its etiology is still unknown. Additionally, given the current absence of neuroprotective therapies, its treatment remains symptomatic. New advances in molecular neuroscience recently led to the idea that neuronal degeneration may be stopped and that specific neuroprotective strategies could be possible. However, this step will only be attained if the molecular pathways of neuronal cell death involved in PD are better understood. The determination of molecular mechanisms of neuronal death in human brain encounters methodological and biological problems. Therefore, in-vivo and in-vitro models using experimental neurotoxins are essential since they allow the study of degenerating processes as well as new therapeutic approaches.
In this review, we present the recent advances in the knowledge of the molecular mechanisms underlying PD and the contribution of experimental models to this field.
Section snippets
Parkinson's disease
Parkinson's disease, first described by James Parkinson in 1817 (Parkinson, 1817), is a neurodegenerative disorder that can be defined as a syndrome associated with specific neuropathological lesions.
General observations
6-Hydroxydopamine is one of the most common neurotoxins used to experimentally model nigral degeneration in vitro as well as in vivo. 6-OHDA is a hydroxylated analogue of the natural dopamine neurotransmitter. It was originally isolated by Senoh in 1959 (Senoh and Witkop, 1959a, Senoh and Witkop, 1959b, Senoh et al., 1959a, Senoh et al., 1959b). Its biological effects were first demonstrated by Porter et al., 1963, Porter et al., 1965 and Stone et al. (1963), who showed that 6-OHDA induces
Relevance of experimental data for human nigral degeneration
All the data presented here strongly suggest that experimental in-vitro and in-vivo models of PD may help to determine which factors could be critical in the molecular pathways leading to degeneration of nigral cells. However, these results are only indicative and need post-mortem confirmation to estimate the real occurrence of such processes. Only a small amount of data are available to date, probably due to the complexity of obtaining and interpreting results obtained in human samples (see
Conclusion
Throughout this review, we have presented evidence suggesting that experimental models reproduce the main cellular modifications occurring in PD. 6-OHDA, DA and MPTP are able to induce two of the main biochemical defects in PD, namely oxidative stress and mitochondrial inhibitions as well as histological lesions. Other aspects of the human disease are, however, not reproduced (Hantraye, 1998): the precise anatomical lesion, the time course of the disease (decades vs. weeks at best), the
Acknowledgements
This work was supported by INSERM, Université Joseph Fourier and MESR. D.B. holds financial support from Fondation pour la Recherche Médicale (France), Fondation Simone et Cino Del Duca (France) et Fonds National pour la Recherche Scientifique (Belgium). We thank Prof. J.P. Brion, Dr M.C. Galas, Dr D. Gall, Dr P. Laduron, Dr V. Gaveau, Dr R. Hourez and Prof. S.N. Schiffmann for critical reading of the manuscript and Dr F.J. Hemming for English revision.
References (510)
- et al.
Pharmacological protection against the cytotoxicity of 6-hydroxydopamine and H2O2 in chromaffin cells
Eur. J. Pharmacol.
(1995) - et al.
Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
Neuron
(2000) - et al.
MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes
Free Rad. Biol. Med.
(1993) - et al.
The Bcl-2 protein family
Exp. Cell. Res.
(2000) - et al.
Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice
Neuroscience
(1998) - et al.
Apoptosis control by death and decoy receptors
Curr. Opin. Cell. Biol.
(1999) - et al.
p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells
Brain Res.
(1997) - et al.
Extracellular toxicity of 6-hydroxydopamine on PC12 cells
Neurosci. Lett.
(2000) - et al.
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
Neurosci. Lett.
(1994) - et al.
Apoptosis: checkpoint at the mitochondrial frontier
Mutat. Res.
(1999)
Caspases induce cytochrome c release from mitochondria by activating cytosolic factors
J. Biol. Chem.
Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis
Exp. Cell. Res.
Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence
Brain Res.
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases
J. Neurol. Sci.
The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
Biochim. Biophys. Acta
Glucose protection from MPP+-induced apoptosis depends on mitochondrial membrane potential and ATP synthase
Biochem. Biophys. Res. Commun.
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Biochem. Biophys. Res. Commun.
Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes
Biochem. Biophys. Res. Commun.
Characterization of MPP(+)-induced cell death in a dopaminergic neuronal cell line: role of macromolecule synthesis, cytosolic calcium, caspase, and Bcl-2-related proteins
Exp. Neurol.
The iap genes: unique arbitrators of cell death
Trends Cell Biol.
Global cerebral ischemia activates nuclear factor-κB prior to evidence of DNA fragmentation
Mol. Brain Res.
The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents
J. Biol. Chem.
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Neurosci. Lett.
The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9
Cell
Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus
J. Chromatogr.
Wild-type but not Parkinson's disease-related Ala-53→Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli
J. Biol. Chem.
Glutathione peroxidase, glial cells and Parkinson's disease
Neuroscience
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis
Brain Res.
Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide
Nitric Oxide
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues
Psychiatry Res.
Effect of 6-hydroxydopamine on polymerization of tubulin. Protection by superoxide dismutase, catalase, or anaerobic conditions
Biochem. Pharmacol.
Caenorhabditis elegans EGL-1 disrupts the interaction of CED-9 with CED-4 and promotes CED-3 activation
J. Biol. Chem.
Determination of the (R)- and (S)-enantiomers of salsolinol and N- methylsalsolinol by use of a chiral high-performance liquid chromatographic column
J. Chromatogr. B Biomed. Appl.
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
Cell
Mitochondria as the central control point of apoptosis
Trends Cell Biol.
Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- treated rat
Neurosci. Lett.
Frequency of dementia in Parkinson disease
Arch. Neurol.
The Bcl-2 protein family: arbiters of cell survival
Science
Regulation of JNK signaling by GSTp
EMBO J.
Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress
Oncogene
The biochemistry of Parkinson's disease
1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation
Eur. J. Pharmacol.
Brain peroxidase and catalase in Parkinson disease
Arch. Neurol.
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
Neurochem. Res.
Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease
Ann. Neurol.
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
Histol. Histopathol.
Death receptors: signaling and modulation
Science
Glial pathology but absence of apoptotic nigral neurons in long- standing Parkinson's disease
Mov. Disord.
Tumor necrosis factor α and β protect neurons against amyloid β-peptide toxicity: evidence for involvement of a κB-binding factor and attenuation of peroxide and Ca++ accumulation
Proc. Natl. Acad. Sci. USA
Control of apoptosis by Rel/NF-kappaB transcription factors
Oncogene
Cited by (1050)
Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish
2023, European Journal of PharmacologyMicroglial depletion exacerbates motor impairment and dopaminergic neuron loss in a 6-OHDA model of Parkinson's disease
2023, Journal of Neuroimmunology